Cannabics, Eroll develop medical cannabis growing device

Cannabics will receive royalties of up to $8 million with a minimum of $500,000 guaranteed for the 2019 fiscal year.

August 19, 2018 22:13
1 minute read.
Cannabics, Eroll develop medical cannabis growing device

An employee inspects the leaf of a cannabis plant at a medical marijuana plantation in northern Israel.. (photo credit: NIR ELIAS / REUTERS)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Israeli personalized medical cannabis cancer treatment company Cannabics Pharmaceuticals has announced a partnership agreement with Israeli company Eroll Grow Tech, developer of Seedo, a fully-automated growing device designed specifically for cannabis.
Through this new partnership, Cannabics and Seedo will develop the first controlled device for growing medical cannabis at home, ensuring sustainable quality and supply of natural, pesticide free product. The fully-automated grow device will be managed and controlled by an artificial intelligence algorithm and monitored by a smart phone app, using technology successfully implemented by Seedo for recreational growth. The development of the home medical prototype device will begin in the first quarter of 2019.

Cannabics Pharmaceuticals will purchase up to a 20% stake in Seedo. Cannabics will receive royalties of up to $8 million with a minimum of $500,000 guaranteed for the 2019 fiscal year. Seedo will be allotted a warranty for one million Cannabics shares at $2 per share for one year.

Seedo holds a medical cannabis R&D license from Israel’s Ministry of Health. The company’s grow device creates lab conditions in order to optimize plant growth without pesticides, human intervention or agricultural knowledge. Ultimately, the partners plan to develop a product using the same technology that will propagate larger quantities of medical cannabis at the industrial scale.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

ILLUSTRATIVE PHOTO: a woman lights candles on the eve of Shabbat
February 22, 2019
Shabbat candle-lighting times for Israel and U.S.